F. Huang

发表

Design, Pharmacokinetic, and Pharmacodynamic Evaluation of a New Class of Soft Anticholinergics

N. Bodor, A. Juhasz, F. Huang, 2003, Pharmaceutical Research.

Effect of Steady‐State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open‐Label, Fixed‐Sequence Crossover Study

N. Strelkowa, M. Elgadi, S. Haertter, 2017, Journal of clinical pharmacology.

Design and rationale for the DIVERSITY study: An open‐label, randomized study of dabigatran etexilate for pediatric venous thromboembolism

L. Brandão, M. Brueckmann, M. Luciani, 2018, Research and practice in thrombosis and haemostasis.

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism

L. Brandão, M. Brueckmann, E. Chalmers, 2017, Thrombosis and Haemostasis.

Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability

M. Brueckmann, M. Luciani, L. Mitchell, 2017, Journal of thrombosis and haemostasis : JTH.

Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials

M. Brueckmann, L. Mitchell, H. Maas, 2018, Thrombosis and Haemostasis.

Effect of the Hepatitis C Virus Protease Inhibitor Faldaprevir on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers

M. Elgadi, J. Sabo, B. Lang, 2014, Antimicrobial Agents and Chemotherapy.

Effect of the HCV protease inhibitor faldaprevir on the pharmacokinetics of an oral

M. Elgadi, J. Sabo, B. Lang, 2014 .

, Male Subjects Virus NS 3 / 4 Protease Inhibitor , in Healthy Steady-State Faldaprevir , a Hepatitis C Mass Balance and Metabolite Profiling of

R. George, C. Yong, B. Latli, 2014 .

Mass Balance and Metabolite Profiling of Steady-State Faldaprevir, a Hepatitis C Virus NS3/4 Protease Inhibitor, in Healthy Male Subjects

Yongmei Li, C. Yong, R. St George, 2014, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open‐Label, Fixed‐Sequence, Crossover Study

M. Trampisch, L. Rowland, A. Schultz, 2018, Basic & clinical pharmacology & toxicology.

Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials

L. Brandão, M. Brueckmann, M. Luciani, 2022, Thrombosis and Haemostasis.

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism

L. Brandão, M. Brueckmann, M. Luciani, 2021, Journal of thrombosis and haemostasis : JTH.

Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.

L. Brandão, M. Brueckmann, M. Luciani, 2019, Blood.

Phase 3, single‐arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design

L. Brandão, M. Brueckmann, M. Luciani, 2018, Research and practice in thrombosis and haemostasis.

Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects

C. Grimaldi, I. Jang, J. Steffgen, 2020, British journal of clinical pharmacology.

Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats

N. Bodor, P. Buchwald, F. Huang, 2008, The Journal of pharmacy and pharmacology.

Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation

S. Haertter, L. R. França, F. Huang, 2017, Canadian Medical Association Journal.

Galantamine Pharmacokinetics, Safety, and Tolerability Profiles Are Similar in Healthy Caucasian and Japanese Subjects

Qinying Zhao, A. Peer, N. Osselaer, 2002, Journal of clinical pharmacology.

Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β‐hydroxysteroid dehydrogenase‐1 (HSD1) inhibitor in humans: liver and adipose tissue 11β‐HSD1 inhibition after acute and multiple administrations over 2 weeks

T. Heise, H. Woerle, H. Woerle, 2016, Diabetes, obesity & metabolism.

Efficacy and Safety Differences between Domestic Paclitaxel Drug-Coated Balloons and Metal Bare Stents in the Treatment of ASO of Femoral-Popliteal Arteries Type IIA–C

F. Huang, Fuqing Wei, Fengkui Cui, 2022, Contrast media & molecular imaging.

Evaluation of steady‐state pharmacokinetic interactions between ritonavir‐boosted BILR 355, a non‐nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects

L. Rowland, P. Robinson, M. Castles, 2012, Journal of clinical pharmacy and therapeutics.

Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.

T. Macgregor, M. Taub, P. Robinson, 2011, Basic & clinical pharmacology & toxicology.

Pharmacokinetics of BILR 355 after Multiple Oral Doses Coadministered with a Low Dose of Ritonavir

T. Macgregor, C. Ballow, L. Rowland, 2008, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

T. Macgregor, A. Ring, P. Robinson, 2008, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics, Safety, and Tolerability of Faldaprevir in Patients with Renal Impairment

A. Halabi, M. Elgadi, C. Yong, 2014, Antimicrobial Agents and Chemotherapy.

Receptor binding studies of soft anticholinergic agents

N. Bodor, P. Buchwald, G. Hochhaus, 2001, AAPS PharmSci.

Design and evaluation of new soft anticholinergic agents

Nicholas Bodor, Peter Buchwald, Attila Juhász, 1998 .

Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.

L. Brandão, M. Brueckmann, M. Luciani, 2020, The Lancet. Haematology.

Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers

N. Strelkowa, M. Elgadi, A. Schultz, 2015, Journal of clinical pharmacology.

PHARMACOKINETICS OF FALDAPREVIR AND ANTIRETROVIRALS IN PATIENTS WITH HIV/HCV CO-INFECTION

D. Dieterich, J. Rockstroh, J. Mallolas, 2014 .

Can Mechanistic Static Models for Drug-Drug Interactions Support Regulatory Filing for Study Waivers and Label Recommendations?

S. Peters, J. D. Gómez-Mantilla, F. Huang, 2023, Clinical Pharmacokinetics.

Pharmacokinetic and Safety Assessments of Galantamine and Risperidone after the Two Drugs Are Administered Alone and Together

Qinying Zhao, K. Lasseter, L. Janssens, 2002, Journal of clinical pharmacology.

Dabigatran Etexilate for the Treatment of Acute Venous Thromboembolism in Children: Results of an Open-Label, Phase 2b/3, Randomised Clinical Trial

L. Brandão, M. Brueckmann, M. Luciani, 2020 .

Mass Balance and Metabolite Proﬁling of Steady-State Faldaprevir, a Hepatitis C Virus NS3/4 Protease Inhibitor, in Healthy Male Subjects

R. George, C. Yong, B. Latli, 2014 .

Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open‐label, randomized, three‐way cross‐over trial in healthy participants

M. Elgadi, T. Giessmann, B. Lang, 2016, The Journal of pharmacy and pharmacology.

Effects of ABCB1, UGT1A1, and UGT1A9 Genetic Polymorphisms on the Pharmacokinetics of Sitafloxacin Granules in Healthy Subjects

G. Sun, Yun Liu, Yong-Qing Wang, 2020, Clinical pharmacology in drug development.

Coadministration With Lopinavir and Ritonavir Decreases Exposure to BILR 355, a Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

T. Macgregor, P. Robinson, M. Castles, 2011, Journal of clinical pharmacology.

Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers

N. Strelkowa, M. Elgadi, A. Schultz, 2015, Journal of clinical pharmacology.